News @Gotham

February 14, 2019 - Gotham Therapeutics Strengthens Board of Directors and Scientific Advisory Board

Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, today announced the appointment of Carlo Incerti, M.D., Ph.D. as an independent Board Member. In addition, the company today added Thomas Tuschl, Ph.D. as a Scientific Advisor.

 
nyc-muc-2-blurred.jpg
Gotham-Group.jpg

PRESS RELEASE

Gotham Therapeutics Launches with $54 Million Series A

In October 2018, Gotham Therapeutics debuted with a $54 million Series A financing co-led by founding investor Versant Ventures, Forbion and S.R. One.

UPCOMING EVENT

AACR 2019

Meet the team at the AACR Annual Meeting 2019 at the Georgia World Congress Center, Atlanta, Georgia, USA, March 29 - Apr 3, 2019.

joey-kyber-99425-unsplash.jpg
lucas-davies-499182-unsplash.jpg

UPCOMING EVENT

Drug Discovery Chemistry 2019

Meet the team at Cambridge Healthtech Institute's 14th Annual Drug Discovery Chemistry Conference at San Diego Convention Center, San Diego, California, USA, Apr 08 - 12, 2019.

Stay In Touch! 

Gotham Therapeutics will be at the forefront of epitranscriptomics research and drug discovery. Staying in touch with us means staying up-to-date on the field.

contact.jpg